Precision Neuroscience, founded by a Neuralink co-founder, claims to have conducted its first in-human clinical study to map brain signals via a neural implant
- Founded in 2021 by a co-founder of Neuralink, Elon Musk's brain-computer interface startup, Precision Neuroscience …
Context & Ripple Effects
Precision Neuroscience spent early 2023 positioning itself as the less invasive counterweight to Elon Musk's brain-implant venture, raising a $41M Series B in January on the pitch of a device that tracks disease rather than requiring deep-brain surgery. Weeks later, Neuralink won FDA approval for its own first-in-human study, setting up a two-company race to put electrodes on human brains.
This claim of a completed in-human study mapping brain signals puts Precision on the board in that race — and the trajectory held: by March 2025 the FDA had cleared its 1,024-electrode implant outright, an unusually fast run from first study to regulatory clearance.
First-order effects
- Precision Neuroscience now has human-generated brain-signal data alongside Neuralink, which implanted its first device in January 2024 and opened trial enrollment for paralysis patients — the two startups are no longer competing on paper designs but on clinical results.
- The result validates the thinner, less invasive implant architecture Precision was funded to build, giving investors and regulators a working alternative to Neuralink's approach.
Second-order effects
- Neuralink's head start in headline attention no longer translates into a monopoly on human trials, forcing both companies to compete for the same small pool of trial participants, neurosurgeons, and BCI-focused capital.
- Precision's path from first study to FDA clearance in March 2025 hands rival BCI developers a regulatory template for less invasive devices, lowering the perceived approval risk across the category.
Third-order effects
- If the pattern holds, the BCI market splits along invasiveness lines — Neuralink's implanted Telepathy-style control versus surface-mapping implants aimed at medical monitoring — rather than converging on one device design.
- Regulators gain repeat experience clearing neural implants, which structurally shortens approval timelines for the next wave of entrants beyond these two companies.
The trend: Brain-computer interfaces are moving from animal labs to regulated human trials, with competing implant designs racing each other through the FDA rather than waiting for one winner.